Ulcer healing · patients with Buerger's disease
It is very uncertain whether intravenous prostacyclin analogue changes ulcer healing compared with intravenous prostaglandin analogue (very low certainty).
1 finding from 1 review
Complete relief of pain · patients with Buerger's disease
Intravenous prostacyclin analogue showed no clear difference in complete relief of pain compared with intravenous prostaglandin analogue (low certainty).
1 finding from 1 review
Rate of amputation · patients with Buerger's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ulcer healing · patients with Buerger's disease
(Oral or intravenous) prostanoid showed no clear difference in ulcer healing compared with placebo (moderate certainty).
1 finding from 1 review
Complete relief of rest pain · patients with Buerger's disease
(Oral or intravenous) prostanoid showed no clear difference in complete relief of rest pain compared with placebo (moderate certainty).
1 finding from 1 review
Rate of amputation · patients with Buerger's disease
(Oral or intravenous) prostanoid showed no clear difference in rate of amputation compared with placebo (moderate certainty).
1 finding from 1 review
Disability due to FAP progression Not measured · people with early‐stage TTR‐FAP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life (mental) · people with TTR‐FAP
1 finding from 1 review
Has died · people with TTR‐FAP
It is very uncertain whether diflunisal changes number of participants who died during the trial compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with TTR‐FAP
It is very uncertain whether diflunisal changes number of dropouts due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Number of participants experiencing at least one severe adverse event · people with TTR‐FAP
It is very uncertain whether diflunisal changes number of participants experiencing at least one severe adverse event compared with placebo (very low certainty).
1 finding from 1 review
Disability due to FAP progression (expressed as the change in R‐ODS) Scale from: 0 (worst disability) to 48 (normal) · people with TTR‐FAP
1 finding from 1 review
Severity of peripheral neuropathy (expressed as the change in mNIS+7ALN) Scale from: 0 (normal) to 304 (total impairment) · people with TTR‐FAP
1 finding from 1 review
QoL · people with TTR‐FAP
1 finding from 1 review
Has died · people with TTR‐FAP
Patisiran showed no clear difference in number of participants who died during the trial compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with TTR‐FAP
Patisiran may leads to lower number of dropouts due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Number of participants experiencing at least one severe adverse event · people with TTR‐FAP
Patisiran showed no clear difference in number of participants experiencing at least one severe adverse event compared with placebo (low certainty).
1 finding from 1 review
Severity of peripheral neuropathy (expressed as the change in NIS‐LL) Scale from: 0 (normal) to 88 (total impairment) · people with early‐stage TTR‐FAP
1 finding from 1 review
Disability due to FAP progression Not measured · people with TTR‐FAP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severity of peripheral neuropathy (expressed as the change in mNIS+7Ionis) Scale from: ‐22.3 (normal) to 346.3 (total impairment) · people with TTR‐FAP
1 finding from 1 review